In 585 adults unsuitable for triptans, a single 75 mg dose of rimegepant gave more migraine pain relief at 2 h than placebo (55.9% vs 32.7%; 570 analysed), with similar adverse event rates (12.5% vs 12.1%).
RCTn = 585
Ashina et al. Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial